-
-
Aimei Vaccine's heavy single product is about to enter the harvest period, and its growth momentum is unstoppable
2023-09-05Source:Asdaq News Agency -
As a rare full industry chain vaccine group in China, Aimei Vaccine (06660) announced that its heavy single product is about to enter the harvest period. Last Thursday, the stock price rose rapidly, soaring by 4.99% for the entire day, closing at HK$49.4, with a total market value of HK$59.8 billion. Investors should closely monitor the recent trend of the stock price and make early deployments.
-
-
-
Aimei Vaccine approved for issuing domestic shares with a clear A-share return signal
2023-08-31Source:Sci-Tech Innovation Board Daily -
Aimei Vaccine (06660.HK) issued the latest announcement on August 30, stating that the company has received approval from the China Securities Regulatory Commission to issue non-publicly listed RMB ordinary shares (i.e., domestic shares) to specific entities.
-
-
-
The first in the country! Aimei Vaccine's human rabies mRNA vaccine clinical application has been accepted
2023-06-14Source:People's Daily -
Aimei Vaccine (06660) announced on the 12th that the clinical trial application for human rabies mRNA vaccine under research has been accepted by the CDE. This is the first domestic application for a clinical rabies mRNA vaccine.
-
-
-
Domestic mRNA rabies vaccine obtains first clinical acceptance. Post-COVID vaccines target these areas
2023-06-12Source:The first financial -
On June 10th, information on the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) showed that the clinical trial application for the human rabies mRNA vaccine by domestic private vaccine manufacturer Aimei Vaccine's subsidiary Lifanda Biotech has been accepted. This marks the first domestic rabies mRNA vaccine to apply for clinical trials and is expected to enter clinical trials soon.
-
-
-
The highest protection rate reaches 80.68%. The construction of the mRNA vaccine production line for the Aimei vaccine against COVID-19 has been completed
2023-06-02Source:Shanghai Securities News -
On June 1st, the Hong Kong-listed Aimei vaccine announced that the recently developed mRNA vaccine for the Omicron BA.5 variant of the novel coronavirus (LVRNA012) has completed mid-term analysis of crucial data on its protective efficacy and safety conducted by researchers in China, with the main result showing a maximum protection rate of 80.68%.
-
-
-
The clinical data for the XBB vaccine shows excellent efficacy, and the company has an annual production capacity of over 200 million doses
2023-06-02Source:Sci-Tech Board Daily -
On June 1st, Aimei Vaccine announced the mid-term analysis of the protective efficacy and safety of the self-developed Omicron BA.5 mRNA vaccine in China, showing that the highest protective efficacy reached 80.68%.
-